共 50 条
- [36] Treatment with PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors. Immune-mediated side effects [J]. UROLOGE, 2018, 57 (05): : 543 - 551
- [39] Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line [J]. PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 95 - 106